Literature DB >> 21330210

5-HT(6) receptor and cognition.

Xabier Codony1, Jose Miguel Vela, Maria Javier Ramírez.   

Abstract

Since its discovery in 1993 and subsequent development of selective antagonists, a growing number of studies support the use of serotonin 5-HT(6) receptor antagonism as a promising mechanism for treating cognitive dysfunction. Lately, several studies with structurally different compounds have shown that not only antagonists, but also 5-HT(6) receptor agonists improve learning and memory in animal models. There is even an antagonist, SB-742457, that has completed phase II trials for the treatment of Alzheimer's disease. In addition to describe preclinical and clinical evidence of the effect of 5-HT(6) receptor compounds on cognition, this article will also focus on the purported biochemical and neurochemical mechanisms of action by which 5-HT(6) receptor compounds could influence cognition in health and disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21330210     DOI： 10.1016/j.coph.2011.01.004

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  27 in total

1.  5-HT6 receptor blockade regulates primary cilia morphology in striatal neurons.

Authors:  Matthew Brodsky; Adam J Lesiak; Alex Croicu; Nathalie Cohenca; Jane M Sullivan; John F Neumaier
Journal:  Brain Res       Date:  2017-01-10       Impact factor: 3.252

Review 2.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties.

Authors:  Paweł Zajdel; Krzysztof Marciniec; Grzegorz Satała; Vittorio Canale; Tomasz Kos; Anna Partyka; Magdalena Jastrzębska-Więsek; Anna Wesołowska; Agnieszka Basińska-Ziobroń; Jacek Wójcikowski; Władysława A Daniel; Andrzej J Bojarski; Piotr Popik
Journal:  ACS Med Chem Lett       Date:  2016-04-07       Impact factor: 4.345

5.  Over-expression of 5-HT6 Receptor and Activated Jab-1/p-c-Jun Play Important Roles in Pilocarpine-Induced Seizures and Learning-Memory Impairment.

Authors:  Changyun Liu; Yuxing Wen; Huapin Huang; Wanhui Lin; Mingzhu Huang; Rong Lin; Ying Ma
Journal:  J Mol Neurosci       Date:  2019-01-29       Impact factor: 3.444

6.  Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats.

Authors:  Magdalena Jastrzębska-Więsek; Agata Siwek; Anna Partyka; Bernadeta Szewczyk; Magdalena Sowa-Kućma; Anna Wasik; Marcin Kołaczkowski; Anna Wesołowska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-06-16       Impact factor: 3.000

Review 7.  Serotonin 5-HT6 Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status.

Authors:  Hilda Ferrero; Maite Solas; Paul T Francis; Maria J Ramirez
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

Review 8.  Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.

Authors:  Maria J Ramirez; Mitchell K P Lai; Rosa M Tordera; Paul T Francis
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

9.  5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms.

Authors:  S Woods; N N Clarke; R Layfield; K C F Fone
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 10.  Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy.

Authors:  Mark J Millan; Yves Agid; Martin Brüne; Edward T Bullmore; Cameron S Carter; Nicola S Clayton; Richard Connor; Sabrina Davis; Bill Deakin; Robert J DeRubeis; Bruno Dubois; Mark A Geyer; Guy M Goodwin; Philip Gorwood; Thérèse M Jay; Marian Joëls; Isabelle M Mansuy; Andreas Meyer-Lindenberg; Declan Murphy; Edmund Rolls; Bernd Saletu; Michael Spedding; John Sweeney; Miles Whittington; Larry J Young
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.